Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Her2 Positive Breast Cancer
Download Her2 Positive Breast Cancer full books in PDF, epub, and Kindle. Read online Her2 Positive Breast Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis HER2-Positive Breast Cancer by : Sara Hurvitz
Download or read book HER2-Positive Breast Cancer written by Sara Hurvitz and published by Elsevier Health Sciences. This book was released on 2018-07-26 with total page 264 pages. Available in PDF, EPUB and Kindle. Book excerpt: Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Book Synopsis Handbook of HER2-Targeted Agents in Breast Cancer by : Ricardo H Alvarez
Download or read book Handbook of HER2-Targeted Agents in Breast Cancer written by Ricardo H Alvarez and published by Springer. This book was released on 2016-05-14 with total page 110 pages. Available in PDF, EPUB and Kindle. Book excerpt: This concise handbook provides oncologists and other healthcare providers with crucial updates in the field, including an updated review of the current understanding of the biology of the HER2 pathway, an overview of HER2-testing, and evidence-based discussions of available and emerging HER2-targeted treatment options. An essential clinical text for physicians that screen and treat patients with breast cancer and require an accessible, up-to-date survey of the dynamic treatment landscape.
Book Synopsis Handbook of HER2-targeted agents in breast cancer by : Ricardo H Alvarez
Download or read book Handbook of HER2-targeted agents in breast cancer written by Ricardo H Alvarez and published by Springer. This book was released on 2014-05-28 with total page 96 pages. Available in PDF, EPUB and Kindle. Book excerpt: Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year. Of these cases, approximately 15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes. However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings.
Book Synopsis HER2 Inhibitors—Advances in Research and Application: 2012 Edition by :
Download or read book HER2 Inhibitors—Advances in Research and Application: 2012 Edition written by and published by ScholarlyEditions. This book was released on 2012-12-26 with total page 73 pages. Available in PDF, EPUB and Kindle. Book excerpt: HER2 Inhibitors—Advances in Research and Application: 2012 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about HER2 Inhibitors in a concise format. The editors have built HER2 Inhibitors—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about HER2 Inhibitors in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of HER2 Inhibitors—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Book Synopsis Drugs for HER-2-positive Breast Cancer by : Maria Sibilia
Download or read book Drugs for HER-2-positive Breast Cancer written by Maria Sibilia and published by Springer Science & Business Media. This book was released on 2011-01-06 with total page 110 pages. Available in PDF, EPUB and Kindle. Book excerpt: Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Book Synopsis Breast Cancer Research and Treatment by : Ouissam Al Jarroudi
Download or read book Breast Cancer Research and Treatment written by Ouissam Al Jarroudi and published by Springer Nature. This book was released on 2024-01-04 with total page 371 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book focuses on innovative treatment options for breast cancer, including surgery, radiotherapy, systemic therapy and of course immunotherapy that is changing outcomes in some aggressive breast cancer histotypes. Subsequent chapters also address the ongoing emerging research in the screening, diagnostics, and management of all subtypes of breast cancers. All current landscapes and future perspectives in each molecular subtype: luminal, HER2-positive, and triple-negative breast cancers are discussed within the different chapters. Breast cancer is still the most common cancer and cause of cancer deaths among women worldwide. The improvement of breast cancer outcome appears to be strictly related to the validation of precise biomarkers that enable us to better select personalized approaches in breast cancer management. The closing chapters deal with the challenges of conducting research in the era of precision medicine for cancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike.
Book Synopsis HER2 Inhibitors—Advances in Research and Application: 2013 Edition by :
Download or read book HER2 Inhibitors—Advances in Research and Application: 2013 Edition written by and published by ScholarlyEditions. This book was released on 2013-06-21 with total page 77 pages. Available in PDF, EPUB and Kindle. Book excerpt: HER2 Inhibitors—Advances in Research and Application: 2013 Edition is a ScholarlyBrief™ that delivers timely, authoritative, comprehensive, and specialized information about ZZZAdditional Research in a concise format. The editors have built HER2 Inhibitors—Advances in Research and Application: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about ZZZAdditional Research in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of HER2 Inhibitors—Advances in Research and Application: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Download or read book Her-2 written by Robert Bazell and published by Random House (NY). This book was released on 1998 with total page 248 pages. Available in PDF, EPUB and Kindle. Book excerpt: The dramatic account of a remarkable new breast cancer drug, from its creation to the moving tales of women whose lives it is saving. The chief correspondent of NBC News, Robert Bazell presents the riveting account of how this drug moved from the lab to the bedside.
Book Synopsis Treatment Options in ErbB2 (HER2)-positive Breast Cancer by :
Download or read book Treatment Options in ErbB2 (HER2)-positive Breast Cancer written by and published by . This book was released on 2008 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Recommendations for Use of Trastuzumab (herceptin®) for the Treatment of Her2-positive Breast Cancer by : NHMRC National Breast Cancer Centre (Australia)
Download or read book Recommendations for Use of Trastuzumab (herceptin®) for the Treatment of Her2-positive Breast Cancer written by NHMRC National Breast Cancer Centre (Australia) and published by . This book was released on 2007 with total page 23 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Management of Breast Cancer in Older Women by : Malcolm W. Reed
Download or read book Management of Breast Cancer in Older Women written by Malcolm W. Reed and published by Springer Science & Business Media. This book was released on 2010-01-18 with total page 408 pages. Available in PDF, EPUB and Kindle. Book excerpt: I was looking at Mrs T – all 45 kilos of her – with somewhat puzzled thoughts. I had prescribed her capecitabine at very prudent doses, in view of her 91-year-old kidneys and physiology. She had reduced my treatment even further, “because it was making her tired.” As a result, she was taking a grand total of 500 mg of capecitabine a day. Yet, her metastatic, ER/PR-negative, Her2-positive breast cancer was undoubtedly responding. Her pain was improving and her chest mass was shrinking, as were her lung metastases... What was the secret of that response? Were Mrs T’s kidneys eli- nating even less drug than predicted by her creatinine clearance? Was her sarcopenia altering drug distribution? Was she absorbing more drug than average? Or was her tumor exquisitely sensitive to fluoropyrimidines? “Physicians,” said Voltaire, “pour drugs they know little for diseases they know even less into patients they know no- ing about.” Medicine has made tremendous progress since the eighteenth century. Yet, there are fields where quite a lot remains to be learned. In developed countries, 25% of breast cancers occur in patients aged 75 years and older. Yet, these patients represent only 4% of the population of traditional clinical trials. That ought to let us wonder how relevant data acquired in patients in their 60s are to a nonagenarian. Fortunately, geriatric oncologists have been stepping up to the task and have gen- ated data to help us to treat such patients.
Book Synopsis Surviving Triple-Negative Breast Cancer by : Patricia Prijatel
Download or read book Surviving Triple-Negative Breast Cancer written by Patricia Prijatel and published by Oxford University Press. This book was released on 2012-10-02 with total page 256 pages. Available in PDF, EPUB and Kindle. Book excerpt: After her diagnosis of hormone-negative breast cancer, health journalist Patricia Prijatel did what any reporter would do: start investigating the disease, how it occurs, how it's treated, and how to keep it from recurring. While she learned that important research on triple-negative breast cancer (TNBC) was emerging, she found a noticeable lack of resources on the disease, which differs from hormone-positive breast cancer in important ways, including prognosis and treatment options. Triple-negative breast cancer disproportionately affects younger women and African-American women-and some forms of it can be more dangerous than other types of breast cancer. But there are many reasons to be hopeful, as Prijatel shows in this book. Surviving Triple-Negative Breast Cancer delivers research-based information on the biology of TNBC; the role of genetics, family history, and race; how to navigate treatment options; understanding a pathology report; and a plethora of strategies to reduce the risk of recurrence, including diet and lifestyle changes. In clear, approachable language, Prijatel provides a fact-filled guide based on a vast array of scientific studies. Woven throughout the book are stories of women who have faced TNBC. These are mothers, wives, daughters, and sisters who went through a variety of medical treatments and then got on with life--one competes in triathlons, two had babies after being treated with chemo, one got remarried in her 50s, and one just celebrated the 30th birthday of the son she was nursing when she was diagnosed. Writing with honesty and humor, Prijatel delivers an inspiring message--that TNBC is a disease to take seriously, with proper and occasionally aggressive treatment, but it is not automatically a killer. Most women diagnosed with the disease survive and go on to live full lives. Surviving Triple-Negative Breast Cancer is a roadmap for women who want to be empowered through their treatment and recovery.
Book Synopsis BAG-1 Expression and Function in HER2-positive Breast Cancer by : Natalia H. Robson
Download or read book BAG-1 Expression and Function in HER2-positive Breast Cancer written by Natalia H. Robson and published by . This book was released on 2016 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis BAG-1 Expression and Function in HER2-positive Breast Cancer by : Natalia Robson
Download or read book BAG-1 Expression and Function in HER2-positive Breast Cancer written by Natalia Robson and published by . This book was released on 2016 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Treatment Options in ErbB2 (HER2)-Positive Breast Cancer by : Christian Jackisch
Download or read book Treatment Options in ErbB2 (HER2)-Positive Breast Cancer written by Christian Jackisch and published by . This book was released on 2008 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This issue is a dedicated supplement published in addition to the regular issues of 'Breast Care' focussing on one specific topic. 'Breast Care' is a well-respected, international peer-reviewed journal in Gynecology. Supplement issues are included in the subscription.
Download or read book Her-2 written by Robert Bazell and published by Random House. This book was released on 2011-04-27 with total page 241 pages. Available in PDF, EPUB and Kindle. Book excerpt: Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.
Download or read book HER2 written by Yosef Yarden and published by IOS Press. This book was released on 2000 with total page 166 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book exemplifies the evolution of oncogene HER2-encoded enzyme from its discovery to the stage of a fully recognized target for breast cancer therapy. Intensive research over the last three decades has uncovered major mechanisms that regulate the transformation of a normal tissue to a malignant tumor. However, to the disappointment of many molecular biologists, these significant advances in identifying oncogenes, tumor-suppressors and critical signalling pathways have generated only limited impact in clinical oncology. This frustration may not persist for long: tailor-made drugs developed specifically to recognize molecular targets, and intercept biochemical engines whose intricacy is well understood, are on the verge of revolutionizing contemporary medicine.
